IQVIA Holdings Inc. (NYSE:IQV) Position Lessened by Atlas Capital Advisors Inc.

Atlas Capital Advisors Inc. reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 25.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 290 shares of the medical research company’s stock after selling 100 shares during the period. Atlas Capital Advisors Inc.’s holdings in IQVIA were worth $57,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Synergy Asset Management LLC acquired a new position in IQVIA in the fourth quarter worth approximately $33,000. Lee Danner & Bass Inc. bought a new stake in IQVIA in the fourth quarter worth approximately $44,000. Zions Bancorporation N.A. increased its stake in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of IQVIA in the 4th quarter valued at $60,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price on the stock. Truist Financial restated a “buy” rating and issued a $263.00 target price (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. JPMorgan Chase & Co. lowered their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Finally, Citigroup lowered their target price on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Price Performance

Shares of IQVIA stock opened at $154.63 on Friday. IQVIA Holdings Inc. has a twelve month low of $154.35 and a twelve month high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market cap of $27.26 billion, a P/E ratio of 20.62, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The firm’s 50-day simple moving average is $189.67 and its 200-day simple moving average is $203.82.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.